Molecure is committed to partnering with the world’s leading research institutions in the fight against serious illness. In these partnerships, we seek to leverage our deep scientific expertise in oncology, fibrotic and inflammatory diseases and outstanding capabilities in the discovery and development of small-molecule drugs together with our partners expertise in identifying novel targets and lead compounds to expand and advance our novel small molecule pipeline modulating challenging protein targets with the potential to develop curative treatments.
Commercial Partnership - Galapagos
A key element of Molecure’s strategy is based on partnering with companies and organizations whose strengths complement its own.
In 2020, Molecure entered into an exclusive, high value partnering deal with an upfront payment of Eur27m, with Galapagos for OATD-01/GLPG4716, a first-in-class oral CHIT1 inhibitor for idiopathic pulmonary fibrosis (IPF), further validating our strengths in medicinal chemistry and first/ best-in-class science.
As a result of a portfolio review by Galapagos in 2022, Molecure regained full rights to OATD-01 together with all the related IP and know-how.
Molecure remains committed to the further development of OATD-01 and plans to commence a Phase II trial in patients with sarcoidosis in 2023 (for more information see the pipeline section).
In March 2022, Molecure entered into an option-to-license agreement with Innovation Partnerships at the University of Michigan to develop novel small molecule inhibitors of an undisclosed target, for the treatment of fibrotic diseases. The novel inhibitors were generated and initially validated as a result of a long-standing research collaboration with Michigan State University (MSU). More information